Antibody discovery platform using gene-editing technologies with multi-species platforms (mouse, alpaca, rabbit) and AI-driven antibody drug screening.
$35MSeries A
A $35M Series A for antibody discovery in China signals that non-US biotech platforms are now raising at scale—this isn't a regional play anymore. The multi-species + AI angle suggests the market is moving past single-platform discovery; if you're building biotech tooling (CDMO, protein engineering, screening automation), watch whether Chinese platforms start undercutting Western incumbents on cost while matching quality. The Vivo Capital lead also matters: they back deep-tech infrastructure, so this validates that antibody discovery is now seen as foundational plumbing, not a one-off service.